Novel HIV-1 therapeutics through targeting altered host cell pathways.
The emergence of drug-resistant HIV-1 strains presents a challenge for the design of new drugs. Anti-HIV compounds currently in use are the subject of advanced clinical trials using either HIV-1 reverse transcriptase, viral protease or integrase inhibitors. Recent studies show an increase in the number of HIV-1 variants resistant to anti-retroviral agents in newly infected individuals. Targeting host cell factors involved in the regulation of HIV-1 replication might be one way to combat HIV-1 resistance to the currently available anti-viral agents. A specific inhibition of HIV-1 gene expression could be expected from the development of compounds targeting host cell factors that participate in the activation of the HIV-1 LTR promoter. Here we discuss how targeting the host can be accomplished either by using small molecules to alter the function of the host's proteins such as p53 or cdk9, or by utilizing new advances in siRNA therapies to knock down essential host factors such as CCR5 and CXCR4. Finally, we will discuss how the viral protein interactomes should be used to better design therapeutics against HIV-1.
Coley
William
W
George Washington University, School of Medicine, Department of Microbiology, Immunology and Tropical Medicine, Washington, DC 20037, USA.
Kehn-Hall
Kylene
K
Van Duyne
Rachel
R
Kashanchi
Fatah
F
D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D005814:Genes, Viral; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D034741:RNA, Small Interfering
D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; D018844:Cyclin-Dependent Kinases